Concord Medical Services Holdings Ltd. — FY2013 Form 20-F
Period: Fiscal year ended December 31, 2013. This is an annual filing, not a standalone fourth-quarter report. Financial statements are prepared under U.S. GAAP; amounts below are primarily RMB millions unless stated otherwise.
Business context
Concord operates radiotherapy and diagnostic imaging centers in Chinese hospitals and also runs Chang’an Hospital, acquired in 2012. It reported a network of 144 centers in 81 hospitals across 55 cities and 25 provinces or administrative regions at year-end. Revenue comes from network equipment leasing and management, and hospital medicine and medical services. Chang’an Hospital was consolidated for all of 2013, versus only part of 2012.
Financial performance and liquidity
| Metric | FY2013 | FY2012 | Change / context |
|---|---|---|---|
| Net revenue | 980.6 (US$162.0m) | 662.3 | Up 48.1%; chiefly full-year consolidation of Chang’an Hospital |
| Gross profit / margin | 393.7 / 40.1% | 325.1 / 49.1% | Profit rose 21.1%; margin fell as lower-margin hospital operations formed a larger share |
| Operating income | 180.7 | 206.6 | Down 12.5% |
| Net income | 91.2 | 134.5 | Down 32.2%; attributable to Concord shareholders: 85.9, versus 130.8 |
| Interest expense | 47.0 | 16.3 | Higher borrowing was the principal stated driver |
| Operating cash flow | 259.0 | 259.5 | Nearly flat; receivables increased by 102.2 during 2013 |
| Investing / financing cash flow | (133.5) / 77.7 | (659.3) / 255.9 | 2013 investing outflow included equipment and related deposits |
| Cash at year-end | 283.0 | 75.4 | Restricted cash was an additional 422.1 |
| Bank borrowings | 1,086.2 | 875.5 | Short-term: 488.0; long-term: 598.3, including current portion |
Audited balance-sheet current assets of 1,300.0 exceeded current liabilities of 1,174.7, implying net current assets of approximately 125.4. The filing’s liquidity discussion also cites 221.2, which does not reconcile to those balance-sheet totals. Total assets were 4,093.6 and total equity 2,433.7 at year-end. Reported basic and diluted earnings were RMB0.64 per ordinary share and RMB1.92 per ADS.
Material changes and operating trends
- Network revenue rose to 563.1 from 465.0; hospital medicine and medical-service revenue rose to 180.1 and 237.4, respectively. Together, hospital revenue was 417.5.
- Hospital business carried lower gross margins than the network business, contributing to the consolidated gross-margin decline. Selling expenses doubled to 107.8, while general and administrative expense rose to 105.1.
- Patient treatment cases in the network fell 12.0% year over year, while diagnostic cases increased 32.6%.
- Capital expenditures were 148.6 in 2013, down from 284.7 in 2012. Management estimated 2014 capital expenditures of 250–300, mainly for network expansion and specialty cancer hospitals.
- The company recorded no asset impairment in 2013, compared with 3.4 in 2012 and 333.9 in 2011, including a large 2011 goodwill impairment. Chang’an Hospital goodwill of 292.9 was not impaired in 2013; management reported 10% headroom in the impairment test.
Outlook, risks and unusual items
- Management said cash and expected operating cash flow should cover working capital and capital expenditures for at least 12 months. This outlook should be considered alongside rising debt, restricted cash and substantial planned investment.
- In March 2014, a lender waived its right to demand immediate repayment following covenant non-compliance at December 31, 2013. Chang’an Hospital was also reported not to comply with certain loan terms; its RMB72.5m borrowing was classified as current.
- In January 2014, the board declared a special dividend of US$0.24 per ordinary share, approximately US$32.4m in total. The company said it intended to retain most future funds and earnings for operations and expansion.
- Major risks include dependence on hospital partners and concentrated customer/receivable exposure; long collection cycles (145 average turnover days for network receivables); equipment procurement quotas and permits; Chinese medical-service pricing and regulatory rules; and difficulty recruiting medical professionals.
- Expansion into majority-owned specialty cancer hospitals, including the planned Beijing proton center and Guangzhou project, entails large capital needs, licensing and construction risks, and limited operating experience. Management also cited seasonality, competition, technology changes, foreign-exchange exposure and potential medical-liability claims.
- Tax uncertainty is material: accrued unrecognized tax positions were 117.1 at year-end, and 2013 tax expense included withholding tax and uncertain-tax-position effects. The company also had a 93.4 non-current loan receivable from Chang’an’s non-controlling shareholder; total related loan balance was 101.2, of which 28.7 was overdue. The planned second pledge securing this exposure was not yet registered.
- The independent auditor gave an unqualified opinion on the financial statements and internal controls; management reported effective disclosure controls and internal control over financial reporting as of year-end.
Important facts for investors to verify
- Reconcile the filing’s stated net current assets of 221.2 with the audited balance-sheet calculation of approximately 125.4.
- Confirm the year-end center count: the filing primarily reports 144, but another MD&A passage gives 142.
- Track covenant compliance and the scope and continuing effectiveness of the March 2014 lender waiver, as well as Chang’an Hospital’s loan status.
- Assess collectability of hospital receivables and the related-party loan, including overdue amounts and completion/registration of the collateral pledge.
- Monitor execution, funding, construction and required approvals for planned hospital projects against the 2014 capex estimate and declared dividend.